Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests
Open Access
- 28 May 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 136 (2) , 382-391
Abstract
Cancer patients undergo routine clinical monitoring with an array of blood tests that may carry long‐term prognostic information. We aimed to develop a new prognostic model predicting survival for patients with advanced non‐small cell lung cancer (NSCLC), based on laboratory tests commonly performed in clinical practice. A cohort of 1,161 stage IIIB or IV NSCLC patients was divided into training (n = 773) and testing (n = 388) cohorts. We analyzed the associations of 32 commonly tested laboratory variables with patient survival in the training cohort. We developed a model based on those significant laboratory variables, together with important clinical variables. The model was then evaluated in the testing cohort. Five variables, including albumin, total protein, alkaline phosphatase, blood urea nitrogen and international normalized ratio, were significantly associated with patient survival after stepwise selection. A model incorporating these variables classified patients into low‐, medium‐ and high‐risk groups with median survival of 16.9, 7.2 and 2.1 months, respectively (p < 0.0001). Compared with low‐risk group, patients in the medium‐ and high‐risk groups had a significantly higher risk of death at 1 year, with hazard ratio (HR) of 1.95 (95% CI 1.62–2.36) and 5.22 (4.30–6.34), respectively. These results were validated in the testing cohort. Overall, we developed a prognostic model relying entirely on readily available variables, with similar predictive power to those which depend on more specialized and expensive molecular assays. Further study is necessary to validate and further refine this model, and compare its performance to models based on more specialized and expensive testing.Keywords
Funding Information
- American Cancer Society (123741-RSG-13-003-01-CCE)
- Pennsylvania Department of Health
This publication has 51 references indexed in Scilit:
- Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective reviewBMC Cancer, 2013
- Factors Associated with Referral to Medical Oncology and Subsequent Use of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Population-Based StudyCurrent Oncology, 2013
- Development and Validation of a Prognostic Model Using Blood Biomarker Information for Prediction of Survival of Non–Small-Cell Lung Cancer Patients Treated With Combined Chemotherapy and Radiation or Radiotherapy Alone (NCT00181519, NCT00573040, and NCT00572325)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working GroupClinical Cancer Research, 2011
- Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor OutcomeClinical Cancer Research, 2011
- Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literatureNutrition Journal, 2010
- Are RAS mutations predictive markers of resistance to standard chemotherapy?Nature Reviews Clinical Oncology, 2009
- Epidemiology of Lung Cancer Prognosis: Quantity and Quality of Life2009
- Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapyPharmacogenetics and Genomics, 2008
- Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimationStatistics in Medicine, 2004